Huntington's disease – clinical signs, symptoms, presymptomatic diagnosis, and diagnosis

Author(s):  
Kathleen M. Shannon
The Lancet ◽  
1980 ◽  
Vol 315 (8158) ◽  
pp. 9-11 ◽  
Author(s):  
A.N. Moshell ◽  
S.F. Barrett ◽  
R.E. Tarone ◽  
J.H. Robbins

2008 ◽  
Vol 275 (1645) ◽  
pp. 1865-1874 ◽  
Author(s):  
Kate Littin ◽  
Abraham Acevedo ◽  
William Browne ◽  
Joanne Edgar ◽  
Mike Mendl ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Emanuela Paldino ◽  
Carmela Giampà ◽  
Elena Montagna ◽  
Cecilia Angeloni ◽  
Francesca R. Fusco

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease due to an expansion of a trinucleotide repeats in IT15 gene encoding for the protein huntingtin. Motor dysfunction, cognitive decline, and psychiatric disorder are typical clinical signs of HD. In HD, mutated huntingtin causes a major loss of brain derived neurotrophic factor (BDNF), causing striatal atrophy. Moreover, a key involvement of BDNF was observed in the synaptic plasticity that controls the acquisition and/or consolidation of certain forms of memory. We studied changes in hippocampal BDNF and in CREB in the R6/2 mouse model of HD. Moreover, we investigated if the beneficial effects of systemically administered recombinant BDNF observed in the striatum and cortex had an effect also on the hippocampus. Osmotic minipumps that chronically released recombinant BDNF or saline solution from 4 weeks of age until euthanasia were implanted into R6/2 and wild type mice. Our data show that BDNF is severely decreased in the hippocampus of R6/2 mice, while BDNF treatment restored its physiological levels. Moreover, the chronic administration of recombinant BDNF promoted the increment of phosphorylated CREB protein. Our study demonstrates the involvement of hippocampus in the pathology of R6/2 model of HD and correlates the beneficial effects of BDNF administration with increased hippocampal levels of BDNF and pCREB.


1992 ◽  
Vol 161 (4) ◽  
pp. 481-488 ◽  
Author(s):  
Audrey Tyler ◽  
Michael Morris ◽  
Lazarus Lazarou ◽  
Linda Meredith ◽  
Jennifer Myring ◽  
...  

Between 1987 and 1990 a large series of at-risk individuals has been referred to our Huntington's disease (HD) presymptomatic testing programme. A detailed protocol for assessment and counselling has been followed. Out of 238 serious inquiries, 36% were potentially suitable for the testing programme, but 19% chose not to continue. Reasons for exclusion included the presence of clinical features of HD and being under the age of 18 years. Out of 40 final results given to 38 individuals, 23 indicated a lowered risk, 11 an increased risk, while five results were uninformative, two of these becoming informative on repeat testing. This series contained more women than men, and was disproportionately from the higher socio-economic groups. Motives for requesting a test principally related to child-bearing, informing existing children, and planning for the future. No significant psychiatric symptoms have been reported in the short term, but difficult counselling problems were presented by the high proportion of applicants who already showed clinical signs of HD. It is concluded that a detailed counselling protocol is essential in testing for HD, as many applicants are ill-prepared; this will assume even greater importance when the HD gene is identified and a test for specific mutations is available. The experience of presymptomatic testing for HD provides important general lessons which are likely to be applicable to other inherited neurological and psychiatric disorders.


2009 ◽  
Vol 13 (6) ◽  
pp. 717-720 ◽  
Author(s):  
Maria Elisa Alonso ◽  
Adriana Ochoa ◽  
Ana Luisa Sosa ◽  
Yaneth Rodríguez ◽  
Mireya Chávez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document